DERMAGNOSTIX

PsorX (CE-IVD)

First molecular test for differential diagnosis of psoriasis und eczema

Based on the gene expression of NOS2 and CCL27, PsorX detects the molecular signature of psoriasis versus eczema supporting the differential diagnosis of these diseases.

Psoriasis and eczema are amongst the most common inflammatory skin diseases. Up to 50% of these patients present diagnostic challenges due to a substantial overlap in clinical appearance. Biologics and small-molecule inhibitors tailored for either psoriasis or eczema may therefore fall short of their therapeutic potential.

PsorX-LabDisk accurately and efficiently distinguishes these diseases. Simple. And at the point of need.

SIMPLE
Sample in, answer out!

QUICK
Quick results (approx. 2h) enable timely clinician decisions.

COST-EFFICIENT
All required reagents are included in the LabDisk in miniature scale.

PRECISE
Reliable, objective and valid results anywhere at any time.

www.dermagnostix.com

Publications

Discover the research behind our products

Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema.
Quaranta, M. et al. (2014), Science translational medicine, 6(244)

A novel molecular disease classifier for psoriasis and eczema.
Garzorz-Stark, N., et al. (2016), Experimental dermatology, 25(10)

Gene Expression–Based Molecular Test as Diagnostic Aid for the Differential Diagnosis of Psoriasis and Eczema in Formalin-Fixed and Paraffin-Embedded Tissue, Microbiopsies, and Tape Strips.
Fischer, F., et al. (2023), Journal of Investigative Dermatology

Find all our research publications on our website.
www.dermagnostix.com/research

Would you like to learn more about our molecular diagnostic solution? Schedule a non-binding initial consultation with us!

Email: customer@dermagnostix.com
Phone: +49 761 60046010*
Website: www.dermagnostix.com

*Availability Mon-Fri, 9 AM - 3 PM

DERMAGNOSTIX